← Back to Search

Enalapril for Endovascular Thrombectomy (DETECT Trial)

Phase 2
Waitlist Available
Led By Aristeidis H Katsanos, MD
Research Sponsored by Hamilton Health Sciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 18 months
Awards & highlights

Summary

This trial is testing whether intensive blood pressure control immediately after successful endovascular stroke thrombectomy can improve patient outcomes.

Eligible Conditions
  • Mechanical Thrombectomy
  • Endovascular Thrombectomy
  • Vascular Occlusion
  • Stroke
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean enrollment rate.
Number of participants with treatment allocation change.
Secondary outcome measures
Absolute difference in flow velocity measurements in transcranial Doppler.
Absolute difference in the NIH Stroke Scale change at day 1.
Absolute difference in the NIH Stroke Scale change at day 2.
+1 more
Other outcome measures
Absolute difference in final infarct volumes.
Absolute difference in hospital stay.
Absolute difference in mean systolic blood pressure values.
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intensive Blood Pressure managementExperimental Treatment3 Interventions
Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
Group II: Standard Blood Pressure managementActive Control3 Interventions
Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enalapril
2016
Completed Phase 4
~13690
Labetalol
2020
Completed Phase 4
~2490
Hydralazine
2020
Completed Phase 4
~940

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationLead Sponsor
369 Previous Clinical Trials
300,451 Total Patients Enrolled
Aristeidis H Katsanos, MDPrincipal InvestigatorHamilton General Hospital, Hamilton Health Sciences
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top